{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:09:05Z","timestamp":1780664945740,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Joint Fund for Innovation and Development of Hubei Provincial Natural Science Foundation","award":["2025AFD788"],"award-info":[{"award-number":["2025AFD788"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12015-026-11138-0","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:57:51Z","timestamp":1777395471000},"page":"2266-2279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cell Therapy and Graft Engineering for Chronic Graft-versus-host Disease"],"prefix":"10.1007","volume":"22","author":[{"given":"Ziyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"3","key":"11138_CR1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia, M. H., et al. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biology Of Blood And Marrow Transplantation, 21(3), 389\u2013401e1.","journal-title":"Biology Of Blood And Marrow Transplantation"},{"issue":"12","key":"11138_CR2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich, A. H., et al. (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology Of Blood And Marrow Transplantation, 11(12), 945\u2013956.","journal-title":"Biology Of Blood And Marrow Transplantation"},{"issue":"1","key":"11138_CR3","doi-asserted-by":"crossref","first-page":"106222","DOI":"10.1016\/j.htct.2025.106222","volume":"48","author":"MK Amin","year":"2026","unstructured":"Amin, M. K., et al. (2026). Outcomes after bone marrow versus peripheral blood haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis. Hematol Transfus Cell Ther, 48(1), 106222.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"16","key":"11138_CR4","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti, C., et al. (2012). Peripheral-blood stem cells versus bone marrow from unrelated donors. New England Journal Of Medicine, 367(16), 1487\u20131496.","journal-title":"New England Journal Of Medicine"},{"issue":"4","key":"11138_CR5","doi-asserted-by":"crossref","first-page":"Cd010189","DOI":"10.1002\/14651858.CD010189.pub2","volume":"2014","author":"U Holtick","year":"2014","unstructured":"Holtick, U., et al. (2014). Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Systematic Review, 2014(4), Cd010189.","journal-title":"Cochrane Database Systematic Review"},{"issue":"3","key":"11138_CR6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41409-021-01551-z","volume":"57","author":"WA Bethge","year":"2022","unstructured":"Bethge, W. A., et al. (2022). Results of a multicenter phase I\/II trial of TCR\u03b1\u03b2 and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. Bone Marrow Transplantation, 57(3), 423\u2013430.","journal-title":"Bone Marrow Transplantation"},{"issue":"4","key":"11138_CR7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41409-019-0725-8","volume":"55","author":"M Leick","year":"2020","unstructured":"Leick, M., et al. (2020). Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. Bone Marrow Transplantation, 55(4), 758\u2013762.","journal-title":"Bone Marrow Transplantation"},{"issue":"25","key":"11138_CR8","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade, J., et al. (2023). Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. New England Journal Of Medicine, 388(25), 2338\u20132348.","journal-title":"New England Journal Of Medicine"},{"issue":"36","key":"11138_CR9","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer, R. J., et al. (2017). Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. Journal Of Clinical Oncology, 35(36), 4003\u20134011.","journal-title":"Journal Of Clinical Oncology"},{"issue":"3","key":"11138_CR10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser, R., et al. (2021). Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. New England Journal Of Medicine, 385(3), 228\u2013238.","journal-title":"New England Journal Of Medicine"},{"issue":"22","key":"11138_CR11","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"138","author":"C Cutler","year":"2021","unstructured":"Cutler, C., et al. (2021). Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood, 138(22), 2278\u20132289.","journal-title":"Blood"},{"issue":"21","key":"11138_CR12","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos, D., et al. (2017). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood, 130(21), 2243\u20132250.","journal-title":"Blood"},{"issue":"1","key":"11138_CR13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620717741860","volume":"9","author":"L Hill","year":"2018","unstructured":"Hill, L., et al. (2018). New and emerging therapies for acute and chronic graft versus host disease. Ther Adv Hematol, 9(1), 21\u201346.","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"11138_CR14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-023-01022-z","volume":"20","author":"N Kadri","year":"2023","unstructured":"Kadri, N., et al. (2023). Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cellular & Molecular Immunology, 20(6), 613\u2013625.","journal-title":"Cellular & Molecular Immunology"},{"issue":"7","key":"11138_CR15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2016-05-715896","volume":"128","author":"C McDonald-Hyman","year":"2016","unstructured":"McDonald-Hyman, C., et al. (2016). Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood, 128(7), 1013\u20131017.","journal-title":"Blood"},{"issue":"1","key":"11138_CR16","first-page":"pCd009768","volume":"1","author":"SA Fisher","year":"2019","unstructured":"Fisher, S. A., et al. (2019). Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Systematic Review, 1(1), pCd009768.","journal-title":"Cochrane Database Systematic Review"},{"key":"11138_CR17","doi-asserted-by":"crossref","first-page":"761616","DOI":"10.3389\/fimmu.2021.761616","volume":"12","author":"K Kelly","year":"2021","unstructured":"Kelly, K., & Rasko, J. E. J. (2021). Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. Frontiers In Immunology, 12, 761616.","journal-title":"Frontiers In Immunology"},{"issue":"4","key":"11138_CR18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jcyt.2014.11.005","volume":"17","author":"A Theil","year":"2015","unstructured":"Theil, A., et al. (2015). Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy, 17(4), 473\u2013486.","journal-title":"Cytotherapy"},{"issue":"6","key":"11138_CR19","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.ymthe.2022.02.025","volume":"30","author":"S Landwehr-Kenzel","year":"2022","unstructured":"Landwehr-Kenzel, S., et al. (2022). Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Molecular Therapy, 30(6), 2298\u20132314.","journal-title":"Molecular Therapy"},{"issue":"22","key":"11138_CR20","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth, J., et al. (2011). Interleukin-2 and regulatory T cells in graft-versus-host disease. New England Journal Of Medicine, 365(22), 2055\u20132066.","journal-title":"New England Journal Of Medicine"},{"issue":"21","key":"11138_CR21","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1182\/bloodadvances.2021006625","volume":"6","author":"JS Whangbo","year":"2022","unstructured":"Whangbo, J. S., et al. (2022). A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv, 6(21), 5786\u20135796.","journal-title":"Blood Adv"},{"issue":"18","key":"11138_CR22","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.2024026446","volume":"145","author":"EH Meyer","year":"2025","unstructured":"Meyer, E. H., et al. (2025). Donor regulatory T-cell therapy to prevent graft-versus-host disease. Blood, 145(18), 2012\u20132024.","journal-title":"Blood"},{"issue":"2","key":"11138_CR23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/cei.12887","volume":"187","author":"A Theil","year":"2017","unstructured":"Theil, A., et al. (2017). T cell receptor repertoires after adoptive transfer of expanded allogeneic regulatory T cells. Clinical And Experimental Immunology, 187(2), 316\u2013324.","journal-title":"Clinical And Experimental Immunology"},{"key":"11138_CR24","doi-asserted-by":"crossref","unstructured":"Bolivar-Wagers, S. (2022). Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses. JCI Insight, 7(17).","DOI":"10.1172\/jci.insight.160674"},{"issue":"Supplement 1","key":"11138_CR25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2025-276","volume":"146","author":"A Salhotra","year":"2025","unstructured":"Salhotra, A., et al. (2025). First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Blood, 146(Supplement 1), 276\u2013276.","journal-title":"Blood"},{"key":"11138_CR26","unstructured":"Center, C. H. M. (2025). Allogeneic CD6 Chimeric antigen receptor T regulatory cells (CD6-CAR Tregs) for the treatment of patients with chronic graft versus host disease after allogeneic hematopoietic. Cell Transplantation. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05993611"},{"issue":"12","key":"11138_CR27","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jcyt.2024.07.013","volume":"26","author":"MP Lauener","year":"2024","unstructured":"Lauener, M. P., et al. (2024). Expansion and characterization of immune suppressive CD56(bright)Perforin(-) regulatory-like natural killer cells in chronic graft-versus-host disease. Cytotherapy, 26(12), 1472\u20131483.","journal-title":"Cytotherapy"},{"issue":"12","key":"11138_CR28","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3324\/haematol.2014.108407","volume":"99","author":"VD Kheav","year":"2014","unstructured":"Kheav, V. D., et al. (2014). Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Haematologica, 99(12), 1860\u20131867.","journal-title":"Haematologica"},{"key":"11138_CR29","doi-asserted-by":"crossref","first-page":"102654","DOI":"10.1016\/j.coi.2025.102654","volume":"97","author":"X Zhang","year":"2025","unstructured":"Zhang, X., et al. (2025). Approved and emerging therapies for glucocorticoid-refractory chronic graft-versus-host disease. Current Opinion In Immunology, 97, 102654.","journal-title":"Current Opinion In Immunology"},{"key":"11138_CR30","doi-asserted-by":"crossref","unstructured":"Lucchini, G. (2010). Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. In Biol blood marrow transplant. pp. 1293\u2013301.","DOI":"10.1016\/j.bbmt.2010.03.017"},{"issue":"5","key":"11138_CR31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/bmt.2016.347","volume":"52","author":"Z Liu","year":"2017","unstructured":"Liu, Z., et al. (2017). Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results. Bone Marrow Transplantation, 52(5), 704\u2013710.","journal-title":"Bone Marrow Transplantation"},{"issue":"10","key":"11138_CR32","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/sctm.20-0099","volume":"9","author":"E Boberg","year":"2020","unstructured":"Boberg, E., et al. (2020). Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study. Stem Cells Transl Med, 9(10), 1190\u20131202.","journal-title":"Stem Cells Transl Med"},{"key":"11138_CR33","doi-asserted-by":"crossref","unstructured":"Kim, N. (2024). Repeated Infusions of Bone-marrow-derived mesenchymal stem cells over 8 weeks for steroid-refractory chronic graft-versus-host disease: a prospective, Phase I\/II clinical study. International Journal Of Molecular Sciences, 25(12).","DOI":"10.3390\/ijms25126731"},{"issue":"7","key":"11138_CR34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","volume":"27","author":"CL Kitko","year":"2021","unstructured":"Kitko, C. L., et al. (2021). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transplant Cell Ther, 27(7), 545\u2013557.","journal-title":"Transplant Cell Ther"},{"issue":"24","key":"11138_CR35","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2015-09-668251","volume":"127","author":"A Kariminia","year":"2016","unstructured":"Kariminia, A., et al. (2016). Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3\u2009+\u2009NK cells. Blood, 127(24), 3082\u20133091.","journal-title":"Blood"},{"issue":"7","key":"11138_CR36","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-018-0092-x","volume":"53","author":"D Wolff","year":"2018","unstructured":"Wolff, D., et al. (2018). Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transplantation, 53(7), 832\u2013837.","journal-title":"Bone Marrow Transplantation"},{"issue":"8","key":"11138_CR37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jcyt.2017.05.002","volume":"19","author":"M Jurado","year":"2017","unstructured":"Jurado, M., et al. (2017). Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I\/II study. Cytotherapy, 19(8), 927\u2013936.","journal-title":"Cytotherapy"},{"issue":"11","key":"11138_CR38","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41591-020-1050-x","volume":"26","author":"AJC Bloor","year":"2020","unstructured":"Bloor, A. J. C., et al. (2020). Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nature Medicine, 26(11), 1720\u20131725.","journal-title":"Nature Medicine"},{"issue":"6","key":"11138_CR39","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41591-024-02990-z","volume":"30","author":"K Kelly","year":"2024","unstructured":"Kelly, K., et al. (2024). Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease. Nature Medicine, 30(6), 1556\u20131558.","journal-title":"Nature Medicine"},{"issue":"2","key":"11138_CR40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","volume":"10","author":"R Huang","year":"2024","unstructured":"Huang, R., et al. (2024). Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial. JAMA Oncol, 10(2), 220\u2013226.","journal-title":"JAMA Oncol"},{"issue":"24","key":"11138_CR41","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","volume":"34","author":"L Gao","year":"2016","unstructured":"Gao, L., et al. (2016). Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation. Journal Of Clinical Oncology, 34(24), 2843\u20132850.","journal-title":"Journal Of Clinical Oncology"},{"issue":"4","key":"11138_CR42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/stcltm\/szac003","volume":"11","author":"MDM Mac\u00edas-S\u00e1nchez","year":"2022","unstructured":"Mac\u00edas-S\u00e1nchez, M. D. M., et al. (2022). Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience. Stem Cells Transl Med, 11(4), 343\u2013355.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"11138_CR43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4196\/kjpp.2016.20.1.63","volume":"20","author":"HG Yi","year":"2016","unstructured":"Yi, H. G., et al. (2016). Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. The Korean Journal Of Physiology & Pharmacology : Official Journal Of The Korean Physiological Society And The Korean Society Of Pharmacology, 20(1), 63\u201367.","journal-title":"The Korean Journal Of Physiology & Pharmacology : Official Journal Of The Korean Physiological Society And The Korean Society Of Pharmacology"},{"issue":"18","key":"11138_CR44","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1182\/bloodadvances.2022009646","volume":"7","author":"X Zhang","year":"2023","unstructured":"Zhang, X., et al. (2023). Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice. Blood Adv, 7(18), 5359\u20135373.","journal-title":"Blood Adv"},{"issue":"7","key":"11138_CR45","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41409-025-02553-x","volume":"60","author":"M Lysandrou","year":"2025","unstructured":"Lysandrou, M., et al. (2025). Regulatory T cell therapy for Graft-versus-Host Disease. Bone Marrow Transplantation, 60(7), 933\u2013939.","journal-title":"Bone Marrow Transplantation"},{"key":"11138_CR46","doi-asserted-by":"crossref","unstructured":"Hefazi, M., Bolivar-Wagers, S., & Blazar, B. R. (2021). Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges. International Journal of Molecular Sciences, 22(18).","DOI":"10.3390\/ijms22189676"},{"issue":"1","key":"11138_CR47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","volume":"133","author":"P Trzonkowski","year":"2009","unstructured":"Trzonkowski, P., et al. (2009). First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4\u2009+\u2009CD25+CD127\u2009\u2013\u2009T regulatory cells. Clinical Immunology, 133(1), 22\u201326.","journal-title":"Clinical Immunology"},{"issue":"1","key":"11138_CR48","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1038\/s41467-024-47575-z","volume":"15","author":"DJ Dittmar","year":"2024","unstructured":"Dittmar, D. J., et al. (2024). Donor regulatory T cells rapidly adapt to recipient tissues to control murine acute graft-versus-host disease. Nature Communications, 15(1), 3224.","journal-title":"Nature Communications"},{"issue":"8","key":"11138_CR49","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","volume":"127","author":"CG Brunstein","year":"2016","unstructured":"Brunstein, C. G., et al. (2016). Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood, 127(8), 1044\u20131051.","journal-title":"Blood"},{"issue":"86","key":"11138_CR50","doi-asserted-by":"crossref","first-page":"35611","DOI":"10.18632\/oncotarget.26242","volume":"9","author":"JN Kellner","year":"2018","unstructured":"Kellner, J. N., et al. (2018). Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget, 9(86), 35611\u201335622.","journal-title":"Oncotarget"},{"issue":"26","key":"11138_CR51","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R., & Blazar, B. R. (2017). Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. New England Journal Of Medicine, 377(26), 2565\u20132579.","journal-title":"New England Journal Of Medicine"},{"issue":"23","key":"11138_CR52","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2016-11-752444","volume":"129","author":"J Du","year":"2017","unstructured":"Du, J., et al. (2017). Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood, 129(23), 3121\u20133125.","journal-title":"Blood"},{"issue":"8","key":"11138_CR53","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan, S. G., et al. (2015). Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood, 125(8), 1333\u20131338.","journal-title":"Blood"},{"issue":"17","key":"11138_CR54","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1182\/bloodadvances.2022007611","volume":"7","author":"NP Buxbaum","year":"2023","unstructured":"Buxbaum, N. P., et al. (2023). Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD. Blood Adv, 7(17), 4886\u20134902.","journal-title":"Blood Adv"},{"issue":"1","key":"11138_CR55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","volume":"129","author":"SJ Lee","year":"2017","unstructured":"Lee, S. J. (2017). Classification systems for chronic graft-versus-host disease. Blood, 129(1), 30\u201337.","journal-title":"Blood"},{"issue":"5","key":"11138_CR56","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.bbmt.2020.01.022","volume":"26","author":"JM Kilgour","year":"2020","unstructured":"Kilgour, J. M., et al. (2020). Systematic Review of Patient-Reported Outcome Measures in Graft-versus-Host Disease. Biology Of Blood And Marrow Transplantation, 26(5), e113\u2013e127.","journal-title":"Biology Of Blood And Marrow Transplantation"},{"issue":"2","key":"11138_CR57","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s40883-020-00160-4","volume":"7","author":"HS Satti","year":"2021","unstructured":"Satti, H. S., et al. (2021). Allogeneic Bone Marrow Mesenchymal Stromal Cell Therapy in Patients with Steroid-Refractory Graft Versus Host Disease\u2014a Pilot Study from Pakistan. Regenerative Engineering and Translational Medicine, 7(2), 234\u2013243.","journal-title":"Regenerative Engineering and Translational Medicine"},{"issue":"2","key":"11138_CR58","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00277-018-3523-2","volume":"98","author":"Z Wang","year":"2019","unstructured":"Wang, Z., et al. (2019). Donor-derived marrow mesenchymal stromal cell co-transplantation following a haploidentical hematopoietic stem cell transplantation trail to treat severe aplastic anemia in children. Annals Of Hematology, 98(2), 473\u2013479.","journal-title":"Annals Of Hematology"},{"issue":"9","key":"11138_CR59","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke, J., et al. (2009). Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. The Lancet Oncology, 10(9), 855\u2013864.","journal-title":"The Lancet Oncology"},{"issue":"1","key":"11138_CR60","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","volume":"128","author":"J Koreth","year":"2016","unstructured":"Koreth, J., et al. (2016). Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood, 128(1), 130\u2013137.","journal-title":"Blood"},{"issue":"9","key":"11138_CR61","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","volume":"27","author":"Z DeFilipp","year":"2021","unstructured":"DeFilipp, Z., et al. (2021). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplant Cell Ther, 27(9), 729\u2013737.","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"11138_CR62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/1744666X.2023.2279188","volume":"20","author":"A Salhotra","year":"2024","unstructured":"Salhotra, A., et al. (2024). A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease. Expert Review Of Clinical Immunology, 20(2), 169\u2013184.","journal-title":"Expert Review Of Clinical Immunology"},{"issue":"2","key":"11138_CR63","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"I Walker","year":"2020","unstructured":"Walker, I., et al. (2020). Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol, 7(2), e100\u2013e111.","journal-title":"Lancet Haematol"},{"issue":"5","key":"11138_CR64","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2013-08-520072","volume":"123","author":"CL Kitko","year":"2014","unstructured":"Kitko, C. L., et al. (2014). Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood, 123(5), 786\u2013793.","journal-title":"Blood"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11138-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11138-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11138-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:30:59Z","timestamp":1780662659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11138-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["11138"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11138-0","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}